- cafead Mar 30, 2021 at 11:43: AM
via Just over a year after Wave Life Sciences cut staffers, threw out a Duchenne muscular dystrophy med and saw its Huntington's disease drug flop in a key test, the waves come crashing down again for the biotech.
In an update posted after-hours Monday evening, Wave said data out of a midstage tests for two of its Huntington’s drugs, WVE-120102 and WVE-120101, were simply too poor to keep going, and they have been axed.
article source
In an update posted after-hours Monday evening, Wave said data out of a midstage tests for two of its Huntington’s drugs, WVE-120102 and WVE-120101, were simply too poor to keep going, and they have been axed.
article source